Regulatory decisions have a ripple effect, first affecting the pharma sponsors, and then the companies tasked to manufacture the drug. Pharmaceutical Technology takes a look at drugs and biologics with recent regulatory verdicts that will likely impact manufacturing volumes. In this ongoing series, we put a spotlight on contracts between pharma companies and contract manufacturing organizations (CMOs).

This analysis covers late April to May and is based on a list of CMOs impacted by regulatory decisions by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and reimbursement authorities like the UK’s National Institute of Health and Care Excellence (NICE). 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharmaceutical companies regularly outsource different steps of drug manufacturing processes like parenteral manufacturing and packaging, solid dose, and small molecule or biologic active pharmaceutical ingredient (API) production, among others. This analysis is based on the GlobalData Pharma Intelligence Center’s Deals database and PharmSource reports. 

Covid-19 vaccines stay in the spotlight

Even as regulatory agencies contemplate the authorization of Omicron-specific Covid-19 vaccines, existing versions continue to make headlines. In early May, the FDA limited the use of Janssen’s Covid-19 vaccine after an updated assessment of the vaccine’s risk of thrombosis with thrombocytopenia syndrome. Janssen Pharmaceutical Companies of Johnson and Johnson’s one-shot vaccine will now be indicated when other vaccines are not accessible or when it is clinically appropriate for adults.  

Several companies have been charged with manufacturing different components of J&J’s vaccine. Hyderabad-based Biological E and Emergent Biosolutions are contracted for biologic API and parenteral manufacture, while biological API and parenteral manufacture and packaging have been outsourced to Catalent and Merck & Co.

FDA decisions since late April for biopharmaceutical drugs and the CMOs contracted to manufacture them. Source: GlobalData Pharmaceutical Intelligence Center

Last month, Emergent sent a notice of material breach of a contract over the same vaccine, which among other things asked for a confirmation that Janssen was in fact winding down the agreement, and does not intend to purchase the minimum amount of product as per a 2020 agreement. In 2021, the US FDA had decreed that about 60 million doses of the vaccine made at Emergent’s factory be discarded after a batch was contaminated.  

In the same realm, Moderna received a positive bump when the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) approved Spikevax’s use in children aged six to 11. Last month, the UK government also announced a collaboration with Moderna to build an mRNA manufacturing facility in the country.

Consequential FDA and EMA decisions

Outside of Covid-19, the FDA and European Commission both approved Novartis’s CAR-T for treating follicular lymphoma in adults. Melbourne, Australia-based Cell Therapies, Munich, Germany-based Fraunhofer-Gesellschaft, and Oxford BioMedica are tasked with manufacturing the biological API for the cell therapy.

The FDA also expanded the label for Supernus Pharmaceuticals’ drug Qelbree to also include attention deficit hyperactivity disorder (ADHD). This was the first non-stimulant drug approved for ADHD in over a decade. Supernus has outsourced the manufacturing of different components to Bachem Holding, Catalent, and Philadelphia, Pennsylvania, US-based PCI Pharma Services.

EMA and NICE decisions since late April for biopharmaceutical drugs and the CMOs contracted to manufacture them.
Source: GlobalData Pharmaceutical Intelligence Center

In late April, the GnRH antagonist relugolix was approved under the brand name Orgovyx in Europe to treat hormone-sensitive prostate cancer. Relugolix was initially developed at Takeda Pharmaceuticals, which then launched Myovant with Roivant Sciences. Saitama, Japan-based Bushu Pharmaceuticals, Feucht, Germany-based Excella,and PCI Pharma Services have been contracted to manufacture different components of this drug.

A few weeks later, the FDA extended the review period for relugolix as a treatment for pain associated with endometriosis, with an updated PDUFA date of August 6. Myovant will launch the drug in collaboration with Pfizer in the US, if approved by then, and receive a $100 million milestone payment from the latter.   

To read the previous edition of this series, click here.